Kodiak Sciences Inc. (KOD): Capital Expenditures
$506.0K
Year ended 2025-12-31
$1.40M
Trailing 12 months to 2026-06-30
-76.1%
3-year compound annual growth
-33.2%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $506.0K | +34.9% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $375.0K | -99.1% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $41.35M | +11.7% | 2026-03-31, From 2023-01-01 |
| 2022-12-31 | $37.02M | +117.4% | 2025-03-27, From 2022-01-01 |
| 2021-12-31 | $17.03M | +346.6% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $3.81M | +772.8% | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | $437.0K | +460.3% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $78.0K | -62.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $209.0K | -72.9% | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | $771.0K | n/a | 2019-03-27, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $506.0K | +34.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $738.0K | +97.3% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.53M | -37.9% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Prokidney Corp. (PROK) | 2025-12-31 | $15.20M | -48.5% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $4.22M | -36.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $5.95M | +715.5% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $794.0K | -30.8% |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗